Nering, Rachel
Merrimack Pharmaceuticals (United States)
2 papers on CoChat
Most cited papers
- Verified
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Arena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., et al. (2016) · Science Translational Medicine
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 93
- Verified
Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors.
Lieu, C. H., Beeram, M., Harb, W. A., Kearns, J. D., Sloss, C. M., Nering, R., Adjei, A. A., & Wolf, B. B. (2015) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesMonoclonal and Polyclonal Antibodies Research
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free